Abstract
Astaxanthin at 0.01 or 0.05% of the diet was supplied to diabetic rats for 12 wk. Astaxanthin intake significantly increased its deposit in plasma, and retained glutathione content, reduced the production of reactive oxygen species, interleukin-6, tumor necrosis factor-α, and monocyte chemoattractant protein-1 in blood and kidney of diabetic rats (P < 0.05). Astaxanthin treatments also significantly decreased plasma levels of C-reactive protein and von Willebrand factor in diabetic rats (P < 0.05). Astaxanthin intake at 0.05% significantly diminished plasminogen activator inhibitor-1 and factor VII activities, enhanced antithrombin-III and protein C activities in circulation (P < 0.05). These results support that astaxanthin could attenuate diabetes associated coagulatory, oxidative, and inflammatory stress.
© 2012 Institute of Food Technologists®
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Anti-Inflammatory Agents / therapeutic use*
-
Anticoagulants / therapeutic use*
-
Antioxidants / therapeutic use
-
Blood Coagulation / drug effects
-
Blood Glucose / drug effects
-
C-Reactive Protein / metabolism
-
Chemokine CCL2 / blood
-
Diabetes Mellitus, Experimental / drug therapy*
-
Glutathione / metabolism
-
Interleukin-6 / blood
-
Kidney / drug effects
-
Male
-
Plasminogen Activator Inhibitor 1 / metabolism
-
Rats
-
Rats, Sprague-Dawley
-
Reactive Oxygen Species / metabolism
-
Tumor Necrosis Factor-alpha / blood
-
Xanthophylls / therapeutic use
Substances
-
Anti-Inflammatory Agents
-
Anticoagulants
-
Antioxidants
-
Blood Glucose
-
Ccl2 protein, rat
-
Chemokine CCL2
-
Interleukin-6
-
Plasminogen Activator Inhibitor 1
-
Reactive Oxygen Species
-
Tumor Necrosis Factor-alpha
-
Xanthophylls
-
astaxanthine
-
C-Reactive Protein
-
Glutathione